LOS ANGELES -- (Business Wire)
Lundin
Law PC, a shareholder rights firm announces a class action lawsuit
against Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”)
(Nasdaq: SGEN) concerning possible violations of federal securities
laws. Investors who purchased or otherwise acquired Seattle Genetics
shares between October 27, 2016 and December 23, 2016, inclusive (the
“Class Period”), are encouraged to contact the firm prior to the March
17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, call Brian Lundin, Esquire,
of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
According to the Complaint, the Company announced that the U.S. Food and
Drug Administration had enforced a clinical hold or partial clinical
hold on initial stage trials of the Company's experimental cancer drug,
vadastuximab talirine, to assess any possible risk of hepatotoxicity.
The Company mentioned that six acute myeloid leukemia patients had been
identified with liver toxicity and that four had died.
When this news was released to the public, the value of Seattle Genetics
dropped, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator
based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170120005489/en/
Contacts:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlawpc.com
Source: Lundin Law PC
© 2024 Canjex Publishing Ltd. All rights reserved.